Aptamers Market Size, Share, Industry, Forecast and Outlook (2024-2031)

Global Aptamers Market Size, Share & Trends Analysis Report By Type, By Application, By Therapeutic Area, By Diagnostic Techniques, By End User, By Region, And Segment Forecasts, 2024-2031

Report Overview

The Global Aptamers Market reached US$ 201.92 million in 2023 and is expected to reach US$ 682.25 billion by 2031, growing at a CAGR of 17.4% during the forecast period 2024-2031.

Aptamers are single-stranded oligonucleotides (DNA, RNA) that specifically bind to target molecules (e.g. proteins, small molecules) like antibodies, and they are extensively used for the development of research tools, diagnosis, and therapeutics. 

In particular, antibody-drug conjugate (ADC) based technology has difficulty in controlling the conjugation of drugs to antibodies and penetrating cancer tissues due to the size of the conjugates. Aptamers are garnering much attention as an alternative to satisfying the unmet needs of antibodies, showing steady demands in various application areas.

Major aspects that boost the aptamers market growth include robust developments of research and development savings in the biotechnology and pharmaceutical sectors, advances in technology, and low cost and high output of aptamers in obligatory to enhance molecules linked to antibodies.

Market Scope

For more details on this report - Request for Sample

Market Dynamics: Drivers

Advancements in the Aptamer  Development Technology

The demand for the global aptamers market is driven by multiple factors. Numerous advantages offered by these small molecules, in comparison to established antibodies, have also led to higher demand for these molecules across a diverse range of medical applications. They are chemically synthesized, which eliminates batch-to-batch variation and demands less time for development. Along with this, continuous advancement in technologies is expected to stimulate market growth.

For instance, in February 2024, Aptamer Group partnered with Neuro-Bio to create tests that can pick up indicative biomarkers for Alzheimer's disease. Aptamer agreed to use its Optimer binders technology, a next-generation aptamer platform that finds application in therapeutic and diagnostic development.

 Also in, In April 2023, researchers from the University of Toronto, Canada, and Northwestern University, IL, USA developed a novel biosensor, utilizing DNA aptamers for the detection of disease biomarkers in complex blood samples.

Moreover, major player's strategies such as partnerships and collaborations, and launches would propel this market growth. For instance, in September 2023, Somalogic extended its 2021 partnership with Novo Nordisk till 2025. Using Somalogic's platform (which includes modified aptamers), Novo Nordisk will continue the drug development efforts in the field of NASH, diabetes, and cardiovascular disorders.

Restraints

Factors such as the high cost of aptamer production, intellectual property issues, limited availability of standardized production methods, stringent regulatory approvals, unfavorable pharmacokinetic properties of aptamers, and lack of awareness are expected to hamper the market.

Segment Analysis

The global aptamers market is segmented based on type, application, therapeutic area, diagnostic techniques, end-user, and region.

The nucleic acid segment accounted for approximately 45.4% of the  global aptamers market share

The nucleic acid finder segment is expected to hold the largest market share over the forecast period. Many companies are investigating the probable use of nucleic acid aptamers in the treatment of a variety of diseases such as age-related muscular degeneration (AMD).

As per Cell Press research publication in November 2022, nucleic acid aptamers as an emerging biosensing platform for the detection and quantification of analytes with high affinity and specificity. Options for DNA aptamer technology are explained through selection, sequencing analysis, and techniques for evaluating affinity and specificity.

Several companies are now investigating how nucleic acid aptamers assist in the treatment of an array of diseases, especially age-related muscle degeneration (AMD). For instance, in June 2021, the U.S. Food and Drug Administration (FDA) granted IVERIC BIO (previously known as Ophthotech Corporation) a written contract under Special Protocol Assessment (SPA) for designing of the GATHER2 phase 3 clinical trial of Zimura for the management of patients with GA secondary to AMD.

Geographical Analysis

North America accounted for approximately 41.7% of the global aptamers  market share 

North America region is expected to hold the largest market share over the forecast period. The key factors driving the market in this region are the rising prevalence of chronic diseases, a well-designed healthcare system, and a growing demand for aptamer studies. The region provides an efficient healthcare infrastructure, along with several research and diagnostic centers that are working on developing aptamer-based technologies for a range of applications.

 The aptamers market in North America has also grown as a result of the existence of significant market players in the area, such as NOXXON Pharma. During the American Society of Clinical Oncology (ASCO) meeting in April 2022, NOXXON Pharma revealed the top-line data of its brain tumor treatment trial, identified as the "NOX-A12." One of the primary applications of aptamers is for the management of cancer, which emphasizes the growing attention being paid to the development of aptamer-based medicines for this purpose. 

The development of aptamers is further supported by quickening technology breakthroughs, medication approvals, and substantial investment and finance. In August 2023, the FDA approved Izervay, the second RNA aptamer, to treat geographic atrophy (GA) resulting from age-related macular degeneration. Iveric Bio, which Astellas bought in July 2023, created the medication, which was formerly known as Zimura. The medication saw sales of JPY 5.3 billion in the first nine months of FY 2023 after its September 2023 US introduction.

COVID-19 Impact Analysis

The COVID-19 pandemic positively impacted the global aptamers market. Utilizing SELEX technology, diagnostic kits and assays based on aptamers can be created to monitor SARS-COV-2 and COVID-19 biomarkers by producing high-affinity neutralizers and probes. As a result, it is anticipated that the launch of diagnostic kits will propel market expansion for illness diagnosis. For instance, in December 2021, the Republic of Indonesia's Ministry of Health approved Achiko AG's COVID-19 diagnostic kit, Aptamex. Aptamex is a second-generation, chemically synthesized, and emerging diagnostic kit for healthcare that was created utilizing DNA aptamer-based technology. 

Peptide aptamers and nucleic acid-based aptamers may be useful in the treatment of COVID-19 infection. The government is thus launching several programs to encourage the R&D of innovative COVID-19 treatments. Aptagen LLC was given a contract of USD 320,000 by the Department of Community & Economic Development in September 2020 to conduct research and develop a new COVID-19 medication.

Market Segmentation

By Type 

• Nucleic Acid Aptamer
• Peptide Aptamer

By Application 

• Diagnostics
• Therapeutics
• Research & Development
• Others

By Therapeutic Area

• Oncology
• Cardiovascular Diseases
• Infectious Diseases
• Autoimmune Disorders
• Others

By Diagnostic Techniques

• Biosensors
•  Immunoassay
•  Flow Cytometry
•  Others

By End-Users

• Pharmaceutical Companies
• Academic and Research centers
• Contract Research Organization
• Others

By Region

• North America

• U.S.
• Canada
• Mexico

• Europe

• Germany
• U.K.
• France
• Spain
• Italy
• Rest of Europe

• South America

• Brazil
• Argentina
• Rest of South America

• Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

• Middle East and Africa

Competitive Landscape

The major global players in the aptamers market include SomaLogic Inc, AM Biotechnologies LLC, Aptagen LLC, Base Pair Biotechnologies, Aptus Biotech, TriLink Biotechnologies, NOVAPTECH, Aptamer Group, Aptamer Sciences Inc, and Creative Biogene among others.

Key Developments

• In January 2024, the leader in cutting-edge biotechnology solutions, Creative Biogene, announced the extension of its stable high-quality cell lines for use in cellular tests for antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).
• In July 2023, Zentek and McMaster University announced the development of a novel aptamer technology platform with an increased aptamer binding affinity. The platform enhances the sensitivity of aptamer-based diagnostics for identifying different biomarkers.
• In May 2023, Aptamer Sciences announced that it had received FDA clearance for its AptaDetect assay for the detection of human papillomavirus (HPV). The assay is a rapid, point-of-care test that can be used to detect HPV in cervical swabs.
• In April 2023, AptaTarget announced that it has entered into a collaboration with AstraZeneca to develop aptamers for the treatment of cancer. The collaboration will focus on the development of aptamers that can target and kill cancer cells.
• In March 2023, QIAGEN announced that it had acquired Epigentek, a company that develops aptamers for use in diagnostics and therapeutics. The acquisition will strengthen QIAGEN's position in the aptamer market and will help the company expand its product portfolio.
• In January 2023, Aptamer Group and BaseCure Therapeutics collaborated on the creation of novel targeted gene treatments. Through this collaboration, particular cell types that might be used as possible delivery systems for siRNA absorption into target cells and tissues are identified. By using this tactic, the business was able to generate fresh prospects for the growth of aptamer applications in the pharmaceutical industry.
• In March 2022, Apatmer Science announced that a candidate material for ‘Corona-19 virus neutralizing aptamer’ has been chosen as a non-clinical support project of the COVID-19 treatments and vaccine new drug development project group.

Why Purchase the Report?

• To visualize the global aptamers market segmentation based on type, application, therapeutic area, diagnostic techniques, end-user, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of global aptamers market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in excel consisting of key products of all the major players.

The global aptamers market report would provide approximately 78 tables, 76 figures, and 184 Pages.

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies